Last updated on May 2018

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)


Brief description of study

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

Detailed Study Description

This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, etc.) or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted.

Clinical Study Identifier: NCT02702492

Contact Investigators or Research Sites near you

Start Over

Stephen Leong, MD

University of Colorado Cancer Center
Aurora, CO United States
  Connect »

Michael Pishvaian, MD, PhD

Georgetown University, Lombardi Comprehensive Cancer Center
Washington, WA United States
  Connect »

Amit Mahipal, MBBS, MPH

Mayo Clinic Rochester
Rochester, MN United States
  Connect »

Daniel Cho, MD

NYU-Laura & Isaac Perlmutter Cancer Center
New York, NY United States
  Connect »

Jordan Berlin, MD

Vanderbilt-Ingram Cancer Center
Nashville, TN United States
  Connect »

Aung Naing, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Albiruni Razak, MB, Bch

Princess Margaret Hospital
Toronto, ON Canada
  Connect »